ALTO NEUROSCIENCE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.96 USD | -0.33% |
|
-7.43% | -.--% |
| May. 21 | Alto Neuroscience, Inc. Appoints Michael Hanley as Chief Operating Officer | CI |
| May. 14 | Alto Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 321.4 | - | - |
| Enterprise Value (EV) 1 | -28.87 | 44.83 | 321.4 |
| P/E ratio | -3.84 x | -3.72 x | -2.29 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | - | - | - |
| EV / FCF | 0.52 x | -0.61 x | -3.53 x |
| FCF Yield | 194% | -165% | -28.3% |
| Price to Book | - | - | - |
| Nbr of stocks (in thousands) | 26,876 | - | - |
| Reference price 2 | 11.96 | 11.96 | 11.96 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -37.81 | -63.6 | -92.62 | -148 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -36.3 | -64.83 | -91.25 | -171 |
| Net income 1 | -27.71 | -36.3 | -61.47 | -87.55 | -138.4 |
| Net margin | - | - | - | - | - |
| EPS 2 | -8.051 | -9.730 | -3.115 | -3.215 | -5.213 |
| Free Cash Flow 1 | - | - | -56 | -74 | -91 |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 11/22/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -11.76 | -14.39 | -16.5 | -17.4 | -15.9 | - | - |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -11.22 | -13.42 | -14 | -15.05 | -16.95 | - | - |
| Net income 1 | -11.22 | -13.42 | -15.16 | -16.09 | -16.58 | -17.68 | -19.37 |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | -6.700 | -0.7600 | -0.6733 | -0.7067 | -0.6700 | -0.6600 | -0.7200 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/21/24 | 5/14/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | 350 | 277 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -56 | -74 | -91 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | 0.6 | 0.6 | 1 |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 11/22/23 | 3/21/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
11.96
USD
Average target price
33.69
USD
Spread / Average Target
+181.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 321M | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- ANRO Stock
- Financials Alto Neuroscience, Inc.
